New investigator-initiated study of the Episealer® knee implant started
Episurf Medical (NASDAQ: EPIS B) today announces the start of a new investigator-initiated clinical study conducted by Prof. H. Vandenneucker at the University hospital in Leuven, Belgium. The study will follow 30 Episealer® patients over 10 years and the goal is to evaluate the efficacy, safety and performance of the Episealer® device in a larger sample size and on the long term. “We appreciate that this independent study with long-term follow-up of Episealer® patients is initiated. We trust that the study will show the potential of Episealer® as long-term treatment alternative for